Xaluritamig for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Nov 2024: Trial registered, NCT06691984
  2. 9 Dec 2024: Trial started, NCT06691984

The trials

NCT06691984: Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

State
Under way
Phase
Phase 3
People
707 taking part
Started
9 Dec 2024
Primary completion
2 Jan 2029
Arms
Xaluritamig
Results
None posted
  1. 18 Nov 2024: Trial registered
  2. 9 Dec 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.